EGF 816

Drug Profile

EGF 816

Alternative Names: EGF-816; EGFRmut-TKI EGF816

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in (Late-stage disease, Combination therapy, Metastatic disease) Solid tumours in Belgium (PO) (NCT02900664)
  • 01 Feb 2015 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy) in Singapore (PO) (NCT02323126)
  • 24 Nov 2014 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in Spain (PO) after November 2014 (EudraCT2014-000726-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top